In contrast, loss-of-function mutations in EZH2, which confer a poor prognosis, have been described in myeloid malignancies, T-ALL, suggesting a tumor-suppressive role for EZH2 in these cell lineages [261,262]. Here, EZH2 is linked to acute lymphoblastic leukemia.